{
  "directed": true,
  "graph": {
    "annotation_list": {
      "MeasurementRelation": [
        "=",
        "~"
      ],
      "MeasurementType": [
        "IC50"
      ],
      "MeasurementUnits": [
        "μM"
      ]
    },
    "annotation_pattern": {
      "ArticleCompoundNumber": ".*",
      "Figure": ".*",
      "MeasurementRangeLower": ".*",
      "MeasurementRangeUpper": ".*",
      "MeasurementValue": ".*",
      "Page": ".*"
    },
    "annotation_url": {
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
    },
    "document_metadata": {
      "authors": "Charles Tapley Hoyt",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "A small assortment of academic articles describing quantitatively described interactions between the MAPT (Tau) protein and small molecules",
      "licenses": "CC BY 4.0",
      "name": "Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease",
      "version": "0.1.0"
    },
    "namespace_pattern": {},
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/9a77ac1a02863bc48b04bab7e8fb0c1d1cec4dd0/external/chebi.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/9a77ac1a02863bc48b04bab7e8fb0c1d1cec4dd0/external/go.belns"
    },
    "path": "tau/bulic2012.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "4": true
        },
        "MeasurementRangeLower": {
          "1.9": true
        },
        "MeasurementRangeUpper": {
          "31": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "Page": {
          "D": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Redox cycling of methylene blue and TAGI potencies. Upper panel (black): Reduced leuco form 2 and structural overlap with inactive phenothiazines 3, 4, and 5. Lower panel (blue): Structural overlap between oxidized form 1 and azure A (6), reduced anthraquinone, 8, and 9, showing the extended π-conjugated system (ND: not determined).",
      "key": "ad189cc4115f31496b422e1ce8540d9d",
      "line": 60,
      "relation": "decreases",
      "source": 10,
      "target": 16
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "3": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "4": true
        },
        "Page": {
          "D": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Redox cycling of methylene blue and TAGI potencies. Upper panel (black): Reduced leuco form 2 and structural overlap with inactive phenothiazines 3, 4, and 5. Lower panel (blue): Structural overlap between oxidized form 1 and azure A (6), reduced anthraquinone, 8, and 9, showing the extended π-conjugated system (ND: not determined).",
      "key": "8e258676e48e8b7d6a8514ee92caf1a1",
      "line": 68,
      "relation": "causesNoChange",
      "source": 13,
      "target": 16
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "4": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "4": true
        },
        "Page": {
          "D": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Redox cycling of methylene blue and TAGI potencies. Upper panel (black): Reduced leuco form 2 and structural overlap with inactive phenothiazines 3, 4, and 5. Lower panel (blue): Structural overlap between oxidized form 1 and azure A (6), reduced anthraquinone, 8, and 9, showing the extended π-conjugated system (ND: not determined).",
      "key": "65f7dde44e5db2b4f8c0660080bf9456",
      "line": 74,
      "relation": "causesNoChange",
      "source": 7,
      "target": 16
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "5": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "4": true
        },
        "Page": {
          "D": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Redox cycling of methylene blue and TAGI potencies. Upper panel (black): Reduced leuco form 2 and structural overlap with inactive phenothiazines 3, 4, and 5. Lower panel (blue): Structural overlap between oxidized form 1 and azure A (6), reduced anthraquinone, 8, and 9, showing the extended π-conjugated system (ND: not determined).",
      "key": "2682d20566821bd25993694216a2264e",
      "line": 80,
      "relation": "causesNoChange",
      "source": 6,
      "target": 16
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "6": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "4": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementValue": {
          "2.6": true
        },
        "Page": {
          "D": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Redox cycling of methylene blue and TAGI potencies. Upper panel (black): Reduced leuco form 2 and structural overlap with inactive phenothiazines 3, 4, and 5. Lower panel (blue): Structural overlap between oxidized form 1 and azure A (6), reduced anthraquinone, 8, and 9, showing the extended π-conjugated system (ND: not determined).",
      "key": "3a3da86b5e4430d8a545141308d066c5",
      "line": 90,
      "relation": "decreases",
      "source": 14,
      "target": 16
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "7": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "4": true
        },
        "MeasurementRelation": {
          "~": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementValue": {
          "2": true
        },
        "Page": {
          "D": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Redox cycling of methylene blue and TAGI potencies. Upper panel (black): Reduced leuco form 2 and structural overlap with inactive phenothiazines 3, 4, and 5. Lower panel (blue): Structural overlap between oxidized form 1 and azure A (6), reduced anthraquinone, 8, and 9, showing the extended π-conjugated system (ND: not determined).",
      "key": "9d996e966e6b19bf932589e4182b716d",
      "line": 100,
      "relation": "decreases",
      "source": 4,
      "target": 16
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "10": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "6": true
        },
        "Page": {
          "F": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Structures of Aβ-aggregation inhibitors evaluated in current or past clinical trials.",
      "key": "950a6f65f2353696db6cf0870d1cf227",
      "line": 120,
      "relation": "decreases",
      "source": 2,
      "target": 17
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "11": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "6": true
        },
        "Page": {
          "F": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Structures of Aβ-aggregation inhibitors evaluated in current or past clinical trials.",
      "key": "133abf8963f16050e5bf0c8828e5d42e",
      "line": 126,
      "relation": "decreases",
      "source": 0,
      "target": 17
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "12": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "6": true
        },
        "Page": {
          "F": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Structures of Aβ-aggregation inhibitors evaluated in current or past clinical trials.",
      "key": "a20e52dbfac9d655faeb6bcc135642d7",
      "line": 132,
      "relation": "decreases",
      "source": 8,
      "target": 17
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "12": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "8": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementValue": {
          "1.8": true
        },
        "Page": {
          "H": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Pyrogallol generic substitution pattern commonly found in multiple polyphenolic Tau aggregation inhibitors such as 12 and 19. Note the structural overlap with the inactive pyrocatechol-substituted epicatechin",
      "key": "10e6ae53f7aa53dfba531a579d8ec3bc",
      "line": 170,
      "relation": "decreases",
      "source": 8,
      "target": 16
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "13": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "6": true
        },
        "Page": {
          "F": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Structures of Aβ-aggregation inhibitors evaluated in current or past clinical trials.",
      "key": "f0fdc1b1233e54a5c98c450bccbb6e7d",
      "line": 138,
      "relation": "decreases",
      "source": 11,
      "target": 17
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "14": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "6": true
        },
        "Page": {
          "F": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Structures of Aβ-aggregation inhibitors evaluated in current or past clinical trials.",
      "key": "0d446cb11d0ecfbf80feebb5d1076b6e",
      "line": 144,
      "relation": "decreases",
      "source": 20,
      "target": 17
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "15": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "6": true
        },
        "Page": {
          "F": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Structures of Aβ-aggregation inhibitors evaluated in current or past clinical trials.",
      "key": "a3aa4bc982770f1f3201337c0e5af16d",
      "line": 150,
      "relation": "decreases",
      "source": 18,
      "target": 17
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "18": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "8": true
        },
        "Page": {
          "H": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Pyrogallol generic substitution pattern commonly found in multiple polyphenolic Tau aggregation inhibitors such as 12 and 19. Note the structural overlap with the inactive pyrocatechol-substituted epicatechin",
      "key": "c66350554d456b9c7149304be70d3bf6",
      "line": 176,
      "relation": "causesNoChange",
      "source": 15,
      "target": 16
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "19": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "8": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementValue": {
          "1.2": true
        },
        "Page": {
          "H": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Pyrogallol generic substitution pattern commonly found in multiple polyphenolic Tau aggregation inhibitors such as 12 and 19. Note the structural overlap with the inactive pyrocatechol-substituted epicatechin",
      "key": "c71cddad9e18a064c963bce8e1be9c64",
      "line": 186,
      "relation": "decreases",
      "source": 3,
      "target": 16
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "33": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "12": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementValue": {
          "30": true
        },
        "Page": {
          "K": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Representative examples of N-phenylamine Tau aggregation inhibitors and structural overlap with the Aβ40 aggregation inhibitor 33 or the nonsteroidal anti-inflammatory drug 34.",
      "key": "dbd6d8fd702dae2e8f5daa383065f9c7",
      "line": 208,
      "relation": "decreases",
      "source": 5,
      "target": 17
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "33": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "12": true
        },
        "Page": {
          "K": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Representative examples of N-phenylamine Tau aggregation inhibitors and structural overlap with the Aβ40 aggregation inhibitor 33 or the nonsteroidal anti-inflammatory drug 34.",
      "key": "407b3efc514ec3ce742eacc60a981089",
      "line": 211,
      "relation": "decreases",
      "source": 5,
      "target": 16
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "34": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "12": true
        },
        "Page": {
          "K": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Representative examples of N-phenylamine Tau aggregation inhibitors and structural overlap with the Aβ40 aggregation inhibitor 33 or the nonsteroidal anti-inflammatory drug 34.",
      "key": "7305c09d9b08b872d905179562399cde",
      "line": 217,
      "relation": "decreases",
      "source": 9,
      "target": 16
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "34": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "12": true
        },
        "Page": {
          "K": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Representative examples of N-phenylamine Tau aggregation inhibitors and structural overlap with the Aβ40 aggregation inhibitor 33 or the nonsteroidal anti-inflammatory drug 34.",
      "key": "388e001f0ae2cffa104355d78c65d43e",
      "line": 218,
      "relation": "decreases",
      "source": 9,
      "target": 17
    },
    {
      "key": "e2cb20258e3ddabe46213253192af347",
      "relation": "partOf",
      "source": 12,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Figure": {
          "13": true
        },
        "Page": {
          "L": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Benzothiazole-based Tau aggregation inhibitors (35, 36, and 37) and Tau NFT binders (38 and 39).",
      "key": "82c29fb630e112fb5b6fba461fe8a0d2",
      "line": 235,
      "relation": "increases",
      "source": 12,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Figure": {
          "13": true
        },
        "Page": {
          "L": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Benzothiazole-based Tau aggregation inhibitors (35, 36, and 37) and Tau NFT binders (38 and 39).",
      "key": "3ccc2edd5948361ad5f9721bcceeb7f2",
      "line": 236,
      "relation": "decreases",
      "source": 12,
      "target": 16
    },
    {
      "key": "68b85039baaa2235f09c14d1598b9aa3",
      "relation": "partOf",
      "source": 21,
      "target": 22
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "41": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "14": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementValue": {
          "5.1": true
        },
        "Page": {
          "L": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Aminothienopyridazines (APTZs) Tau aggregation inhibitors (B/P: blood to plasma ratio).",
      "key": "170376ac841fdadba22ea2ed2e6f093a",
      "line": 261,
      "relation": "decreases",
      "source": 1,
      "target": 16
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "42": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "14": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementValue": {
          "6.3": true
        },
        "Page": {
          "L": true
        }
      },
      "citation": {
        "authors": [
          "Bulic B",
          "Mandelkow E",
          "Pickhardt M"
        ],
        "date": "2013-06-13",
        "db": "PubMed",
        "db_id": "23484434",
        "db_name": "Progress and developments in tau aggregation inhibitors for Alzheimer disease.",
        "first": "Bulic B",
        "journal": "Journal of medicinal chemistry",
        "last": "Mandelkow E",
        "pages": "4135-55",
        "volume": "56"
      },
      "evidence": "Aminothienopyridazines (APTZs) Tau aggregation inhibitors (B/P: blood to plasma ratio).",
      "key": "e2cbcf97953dbfb122a2b79dce781bf9",
      "line": 270,
      "relation": "decreases",
      "source": 19,
      "target": 16
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:10642)",
      "concept": {
        "name": "10642",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "65074c761567da15eab780a0a71b8cfb"
    },
    {
      "bel": "a(CHEBI:112284)",
      "concept": {
        "name": "112284",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "d2f06d45e98316b1f66b16aa260181f2"
    },
    {
      "bel": "a(CHEBI:1457)",
      "concept": {
        "name": "1457",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "7e131f72926927b6127ef98fc8f5c332"
    },
    {
      "bel": "a(CHEBI:18152)",
      "concept": {
        "name": "18152",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "ac509f1067d370c74aa6f8b04cc04167"
    },
    {
      "bel": "a(CHEBI:22580)",
      "concept": {
        "name": "22580",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "d94ed6709524082e787251e18a0de4fc"
    },
    {
      "bel": "a(CHEBI:3441)",
      "concept": {
        "name": "3441",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "7ddcc7eef2eca1017cd3729004ad880a"
    },
    {
      "bel": "a(CHEBI:3647)",
      "concept": {
        "name": "3647",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "945d8c79016350e9774ac146e333c2f2"
    },
    {
      "bel": "a(CHEBI:44932)",
      "concept": {
        "name": "44932",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "300ba9d94e387b9a87d4f32556db5ff9"
    },
    {
      "bel": "a(CHEBI:4806)",
      "concept": {
        "name": "4806",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "55937a32f614e62cfa7e276dd7de5695"
    },
    {
      "bel": "a(CHEBI:6710)",
      "concept": {
        "name": "6710",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a8eae5eb03202e7c690f61d74e82a5bc"
    },
    {
      "bel": "a(CHEBI:6872)",
      "concept": {
        "name": "6872",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "bd143b34d1eea1d5292313a38b687efc"
    },
    {
      "bel": "a(CHEBI:74460)",
      "concept": {
        "name": "74460",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a0ac408dec210e6291dccac39f79cafd"
    },
    {
      "bel": "a(CHEBI:76034)",
      "concept": {
        "name": "76034",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "b4c326b5be96c60567c68201c18527e7"
    },
    {
      "bel": "a(CHEBI:8028)",
      "concept": {
        "name": "8028",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "15f39a88a0dc596fb0bb213cfa164226"
    },
    {
      "bel": "a(CHEBI:87637)",
      "concept": {
        "name": "87637",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "9a520b53ecd5a7a3f29bf7f9d3ac4d12"
    },
    {
      "bel": "a(CHEBI:90)",
      "concept": {
        "name": "90",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "f3b0f81fe8fa27a2364d9e6a50135947"
    },
    {
      "bel": "a(CONSO:CONSO00006)",
      "concept": {
        "name": "CONSO00006",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "bad7f1d7824c4c370cee32506549e388"
    },
    {
      "bel": "a(CONSO:CONSO00018)",
      "concept": {
        "name": "CONSO00018",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "34dd2f1fa683fcd7e9904d4b0d1682d6"
    },
    {
      "bel": "a(CONSO:CONSO00019)",
      "concept": {
        "name": "CONSO00019",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "d1b3bb60b80714de9a006405084dc20a"
    },
    {
      "bel": "a(CONSO:CONSO00020)",
      "concept": {
        "name": "CONSO00020",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "dd242e9099aaebb81bea1973b61880d2"
    },
    {
      "bel": "a(CONSO:CONSO00021)",
      "concept": {
        "name": "CONSO00021",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "76dac1bd487c36ee157a79049ae7c5ee"
    },
    {
      "bel": "a(GO:\"GO:0097418\")",
      "concept": {
        "name": "GO:0097418",
        "namespace": "GO"
      },
      "function": "Abundance",
      "id": "d64bbe1d02d0bc2d26f731869acabf0f"
    },
    {
      "bel": "complex(a(CHEBI:76034), a(GO:\"GO:0097418\"))",
      "function": "Complex",
      "id": "75dbe2d873a80ef3aedad506eca0b7ca",
      "members": [
        {
          "bel": "a(CHEBI:76034)",
          "concept": {
            "name": "76034",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "b4c326b5be96c60567c68201c18527e7"
        },
        {
          "bel": "a(GO:\"GO:0097418\")",
          "concept": {
            "name": "GO:0097418",
            "namespace": "GO"
          },
          "function": "Abundance",
          "id": "d64bbe1d02d0bc2d26f731869acabf0f"
        }
      ]
    }
  ]
}